**Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy.



UROLOGY REFERRAL FORM

Start	Date:	

Single Point of Contact: 724-515-7053 Pharmacy 866-213-9821

FAX: 877-526-8823 Ship To: Patient Office Other

1. Patient Inforn	nation:	Please fax fro	nt and back copy of tl	he insurance card (P	•	ical)	
	Last Name						
Address:					<u> </u>		
	Street OCT:	City	Alternate pho	one number:			
Comorbidities:		,,o.g.co.					
2. Clinical Inform		lease fax recent clinic					
	iation. PI		Any				
Renal Dysfunction Ye	es ☐ No Liver Dysfunct	tion: ☐ Yes ☐ No H	H/H (Hemoglobin/ Hema	atocrit):			
Date and value of las			Date and value of	last Serum PSA			
Date and value of las	st Serum Testosterone		Date of Orchiecton	my			
Prior TI	herapy	Reason for Discont	tinuation of Therapy	Approximate	te Start Date	Approximate End Date	
3. Prescription Inforn	mation:	LEVOL pood o	readination not lists	el el la contract us			
		ii you need a	medication not liste	d please contact us	1 0 444	D-6ill-	
Medication	Strength		Directions		Quantity	Refills	
□ Casodex®	□ 50mg tablets		☐ Take one tablet PO on ☐ Other	•	☐ 30 Tablets ☐ Other	_	
□ Eligard®	☐ 7.5mg once every month ☐22.5mg once every 3 months ☐30mg once every 4 months ☐45mg once every 6 months		□ Inject 1 PFS Sub-Q		☐ 1 Kit		
□ Lupron®	□7.5mg once every 3 months □22.5mg once every 3 months □30mg once every 4 months □45mg once every 6 months		☐ Inject 1 PFS intramuscularly		☐ 1 Kit		
□ Nilandron®	□150mg		☐ Take 2 tablets daily for 30 days ☐ Take 1 tablet daily				
□ Xgeva®	□120mg Vial		☐ Administer Sub-Q every 4 weeks ☐ Other				
□ Zoladex®	□10.8mg PFS □3.6 mg PFS		☐ Inject Sub-Q every 12 weeks into anterior abdominal wall below the navel line. ☐ Other				
Supportive Medications:		Authorization # :				\top	
☐ Aranesp® ☐ Arixtra® ☐ Caphosol® ☐ Emend®	☐ Neupogen® ☐ Nplate®* ☐ Procrit® ☐ Promacta®	□ Zofran® □ Other	Strength/Direction	ns (SIG):	Strength/Direc	ctions (SIG):	
☐ Lovenox®	☐ Sancuso®		Refill #:	QTY:	Refill #:	QTY:	
□ Neulasta®	☐ Zarxio®						\perp
Strength(s): Directions:							
Quantity: Packaging: □ Bott	tles □ AccuPac ^{TI}	тм	**Authorization:				
4. Prescriber and Sh	ipping Information						
Prescriber (print)				ce Contact:			-
	f contact: phone fax		•	persons email:			_
				NPI:		DEA:	
Prescriber's Signatu	ure:nacy and its representative to act as	us an agent to initiate and execute	e the insurance prior authorizati	ion process (NO STAMPS)	Date:		-
	Programs (optional):		o enroll in the pharm		assisted patient sur	oport program	
Patient Signature:		· · · · · · · · · · · · · · · · · · ·			Date:		
6. Insurance Informa	ation:	Please fa	x a copy of the insura	ance card (front & ba	ck)		